Proqr Therapeuti Stock Price, News & Analysis

ProQR Therapeutics N.V. (Nasdaq: PRQR) hosted a virtual Analyst Event on November 18, 2021, highlighting its clinical-stage RNA therapies for genetic eye diseases. Key updates include the Phase 2/3 Illuminate trial for sepofarsen, with top-line results expected in Q1/Q2 2022, showing potential visual acuity improvements. Additionally, data from the QR-421a and QR-1123 trials indicated benefits in vision for Usher syndrome and retinitis pigmentosa patients. ProQR is advancing its pipeline with strategic clinical trials, aiming for impactful RNA therapies.

ProQR Therapeutics N.V. (Nasdaq: PRQR) will host a virtual Analyst Event on November 18, 2021, from 12-2 PM ET. The event will showcase advancements in its clinical pipeline and the Axiomer® RNA editing platform. Key highlights include data from the Phase 1/2 InSight extension study of sepofarsen and an overview of the Phase 2/3 Illuminate trial. Attendees can pre-register for the live webcast or access the archived session on ProQR’s website. ProQR focuses on transformative RNA therapies for genetic eye diseases such as Leber congenital amaurosis and retinitis pigmentosa.

ProQR Therapeutics N.V. (Nasdaq: PRQR) has announced its participation in two upcoming investor conferences. The conferences include the Stifel 2021 Virtual Healthcare Conference on November 15 and the Evercore ISI 4th Annual HealthCONx Conference on December 2. Each session will feature a fireside chat with company management, offering insights into ProQR's innovative RNA therapies aimed at treating genetic eye diseases. Details will be available on ProQR's website, with archived webcasts accessible for 30 days post-event.

ProQR Therapeutics reported Q3 2021 results, showing a net loss of €15.1 million or €0.22 per share, an increase from a €13.2 million loss year-over-year. The company holds €156.1 million in cash and equivalents. Key developments include the anticipated top-line data from the Phase 2/3 Illuminate trial for sepofarsen in late Q1 2022, and a collaboration with Lilly involving a $50 million upfront payment and potential milestones of $1.25 billion. Upcoming analyst event on November 18, 2021, will outline clinical advancements and the Axiomer RNA editing platform.

ProQR Therapeutics (Nasdaq: PRQR) has appointed Theresa Heggie as Chief Commercial Officer, effective immediately. Ms. Heggie brings extensive experience in global rare disease commercialization, previously holding senior roles at Alnylam and Shire. Her appointment coincides with the upcoming top-line data from the Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10, expected in H1 2022. This leadership change is aimed at strengthening the company’s commercial strategy and preparations for the trial results.

ProQR Therapeutics (Nasdaq: PRQR) announced an investor conference call on September 9, 2021, at 8:15 am EDT to discuss the Axiomer RNA editing technology platform after its partnership with Eli Lilly. Axiomer aims to create transformative RNA therapies for genetic eye diseases by inducing specific nucleotide changes using the cell's machinery. The live and archived webcast will be available on their website. This technology could address over 20,000 known G to A mutations causing human diseases, providing significant potential for medical advancements.

ProQR Therapeutics has entered a global licensing and research collaboration with Eli Lilly, focusing on developing RNA editing therapies for genetic disorders affecting the liver and nervous system. ProQR will receive an upfront payment of $20 million and a $30 million equity investment, totaling $50 million. The company is also eligible for up to $1.25 billion in milestone payments and royalties from product sales. The collaboration will utilize ProQR's Axiomer® platform technology, allowing precise RNA edits to potentially reverse over 20,000 disease-causing mutations.

ProQR Therapeutics (Nasdaq: PRQR) announced its participation in the EURETINA virtual congress from September 9-12, 2021, where it will present data from the Phase 1/2 Stellar trial of its investigational RNA therapy QR-421a. This therapy targets vision loss due to mutations in the USH2A gene, the leading cause of combined deafness and blindness. The presentation, led by Dr. David G. Birch, will mark the first public data presentation from the Stellar trial.

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced participation in various upcoming investor conferences focused on RNA therapies for genetic eye diseases. Key events include:

• Citi’s 16th Annual BioPharma Virtual Conference on September 9, 4:10-4:55 pm EDT.
• HC Wainwright 23rd Annual Global Investment Conference available on demand from September 13, 7am EDT.
• Cantor Virtual Global Healthcare Conference on September 28, 3:20-3:50 pm EDT.
• Chardan’s 5th Annual Genetic Medicines Conference on October 5, 4:00-4:30 pm EDT.

Details are available on the company’s website.